254 related articles for article (PubMed ID: 34001209)
1. A systematic dissection of the epigenomic heterogeneity of lung adenocarcinoma reveals two different subclasses with distinct prognosis and core regulatory networks.
Yuan C; Chen H; Tu S; Huang HY; Pan Y; Gui X; Kuang M; Shen X; Zheng Q; Zhang Y; Cheng C; Hong H; Tao X; Peng Y; Yao X; Meng F; Ji H; Shao Z; Sun Y
Genome Biol; 2021 May; 22(1):156. PubMed ID: 34001209
[TBL] [Abstract][Full Text] [Related]
2. Differential
Lin S; Tian C; Li J; Liu B; Ma T; Chen K; Gong W; Wang JM; Huang J
Oncol Rep; 2021 May; 45(5):. PubMed ID: 33786615
[TBL] [Abstract][Full Text] [Related]
3. Integrative epigenomic and high-throughput functional enhancer profiling reveals determinants of enhancer heterogeneity in gastric cancer.
Sheng T; Ho SWT; Ooi WF; Xu C; Xing M; Padmanabhan N; Huang KK; Ma L; Ray M; Guo YA; Sim NL; Anene-Nzelu CG; Chang MM; Razavi-Mohseni M; Beer MA; Foo RSY; Sundar R; Chan YH; Tan ALK; Ong X; Skanderup AJ; White KP; Jha S; Tan P
Genome Med; 2021 Oct; 13(1):158. PubMed ID: 34635154
[TBL] [Abstract][Full Text] [Related]
4. The hyper-activation of transcriptional enhancers in breast cancer.
Li QL; Wang DY; Ju LG; Yao J; Gao C; Lei PJ; Li LY; Zhao XL; Wu M
Clin Epigenetics; 2019 Mar; 11(1):48. PubMed ID: 30867030
[TBL] [Abstract][Full Text] [Related]
5. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
[TBL] [Abstract][Full Text] [Related]
6. Identification and Validation of 7-lncRNA Signature of Epigenetic Disorders by Comprehensive Epigenetic Analysis.
Cao P; Li F; Xiao Y; Hu S; Kong K; Han P; Yue J; Deng Y; Zhao Z; Wu D; Zhang L; Zhao B
Dis Markers; 2022; 2022():5118444. PubMed ID: 35237359
[TBL] [Abstract][Full Text] [Related]
7. Novel genome-wide DNA methylation profiling reveals distinct epigenetic landscape, prognostic model and cellular composition of early-stage lung adenocarcinoma.
Gan J; Huang M; Wang W; Fu G; Hu M; Zhong H; Ye X; Cao Q
J Transl Med; 2024 May; 22(1):428. PubMed ID: 38711158
[TBL] [Abstract][Full Text] [Related]
8. NF-YA Overexpression in Lung Cancer: LUAD.
Bezzecchi E; Ronzio M; Semeghini V; Andrioletti V; Mantovani R; Dolfini D
Genes (Basel); 2020 Feb; 11(2):. PubMed ID: 32075093
[TBL] [Abstract][Full Text] [Related]
9. Multi-omics analysis of genomics, epigenomics and transcriptomics for molecular subtypes and core genes for lung adenocarcinoma.
Zhao Y; Gao Y; Xu X; Zhou J; Wang H
BMC Cancer; 2021 Mar; 21(1):257. PubMed ID: 33750346
[TBL] [Abstract][Full Text] [Related]
10. A novel ferroptosis-related gene signature for prognostic prediction of patients with lung adenocarcinoma.
Jin J; Liu C; Yu S; Cai L; Sitrakiniaina A; Gu R; Li W; Wu F; Xue X
Aging (Albany NY); 2021 Jun; 13(12):16144-16164. PubMed ID: 34115610
[TBL] [Abstract][Full Text] [Related]
11. Super-enhancer mediated upregulation of MYEOV suppresses ferroptosis in lung adenocarcinoma.
Luo S; Luo Y; Wang Z; Yin H; Wu Q; Du X; Xie X
Cancer Lett; 2024 May; 589():216811. PubMed ID: 38490328
[TBL] [Abstract][Full Text] [Related]
12. Exploring and comparing of the gene expression and methylation differences between lung adenocarcinoma and squamous cell carcinoma.
Yang Y; Wang M; Liu B
J Cell Physiol; 2019 Apr; 234(4):4454-4459. PubMed ID: 30317601
[TBL] [Abstract][Full Text] [Related]
13. TENET 2.0: Identification of key transcriptional regulators and enhancers in lung adenocarcinoma.
Mullen DJ; Yan C; Kang DS; Zhou B; Borok Z; Marconett CN; Farnham PJ; Offringa IA; Rhie SK
PLoS Genet; 2020 Sep; 16(9):e1009023. PubMed ID: 32925947
[TBL] [Abstract][Full Text] [Related]
14. Systematical identifications of prognostic meaningful lung adenocarcinoma subtypes and the underlying mutational and expressional characters.
Lv Z; Lei T
BMC Cancer; 2020 Jan; 20(1):56. PubMed ID: 31987030
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of ERBB2 gene overexpression by the formation of super-enhancer with genomic structural abnormalities in lung adenocarcinoma without clinically actionable genetic alterations.
Kaneko S; Takasawa K; Asada K; Shiraishi K; Ikawa N; Machino H; Shinkai N; Matsuda M; Masuda M; Adachi S; Takahashi S; Kobayashi K; Kouno N; Bolatkan A; Komatsu M; Yamada M; Miyake M; Watanabe H; Tateishi A; Mizuno T; Okubo Y; Mukai M; Yoshida T; Yoshida Y; Horinouchi H; Watanabe SI; Ohe Y; Yatabe Y; Saloura V; Kohno T; Hamamoto R
Mol Cancer; 2024 Jun; 23(1):126. PubMed ID: 38862995
[TBL] [Abstract][Full Text] [Related]
16. Development and validation of a novel epigenetic-related prognostic signature and candidate drugs for patients with lung adenocarcinoma.
Wang Z; Embaye KS; Yang Q; Qin L; Zhang C; Liu L; Zhan X; Zhang F; Wang X; Qin S
Aging (Albany NY); 2021 Jul; 13(14):18701-18717. PubMed ID: 34285141
[TBL] [Abstract][Full Text] [Related]
17. Genome-wide analysis of methylation CpG sites in gene promoters identified four pairs of CpGs-mRNAs associated with lung adenocarcinoma prognosis.
Pan X; Ji P; Deng X; Chen L; Wang W; Li Z
Gene; 2022 Feb; 810():146054. PubMed ID: 34737001
[TBL] [Abstract][Full Text] [Related]
18. Predictions of the dysregulated competing endogenous RNA signature involved in the progression of human lung adenocarcinoma.
Yang D; He Y; Wu B; Liu R; Wang N; Wang T; Luo Y; Li Y; Liu Y
Cancer Biomark; 2020; 29(3):399-416. PubMed ID: 32741804
[TBL] [Abstract][Full Text] [Related]
19. A novel lncRNA, LUADT1, promotes lung adenocarcinoma proliferation via the epigenetic suppression of p27.
Qiu M; Xu Y; Wang J; Zhang E; Sun M; Zheng Y; Li M; Xia W; Feng D; Yin R; Xu L
Cell Death Dis; 2015 Aug; 6(8):e1858. PubMed ID: 26291312
[TBL] [Abstract][Full Text] [Related]
20. Functional characterization and clinical significance of super-enhancers in lung adenocarcinoma.
Jiang X; Qin N; Hua T; Wei X; Li Y; Chen C; Gong L; Liu S; Wang C; Yin R; Jiang Y; Dai J; Xu L; Shen H; Ma H
Mol Carcinog; 2022 Aug; 61(8):776-786. PubMed ID: 35596703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
